OMX Copenhagen PI
1.184,85
PKT
+20,97
PKT
+1,80
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen PI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.09.20 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 29.09.20 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 25.09.20 | Novo Nordisk Neutral | UBS AG | |
| 22.09.20 | A.P. Moeller - Maersk A-S (B) overweight | JP Morgan Chase & Co. | |
| 15.09.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 02.09.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 21.08.20 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 21.08.20 | A.P. Moeller - Maersk A-S (B) Hold | Jefferies & Company Inc. | |
| 21.08.20 | A.P. Moeller - Maersk A-S (B) Neutral | JP Morgan Chase & Co. | |
| 20.08.20 | A.P. Moeller - Maersk A-S (B) buy | Deutsche Bank AG | |
| 20.08.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 19.08.20 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 18.08.20 | Novo Nordisk Neutral | UBS AG | |
| 18.08.20 | A.P. Moeller - Maersk A-S (B) buy | Kepler Cheuvreux | |
| 14.08.20 | Novo Nordisk Hold | Kepler Cheuvreux | |
| 11.08.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 10.08.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 07.08.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 07.08.20 | Novo Nordisk Outperform | Bernstein Research | |
| 07.08.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.08.20 | Novo Nordisk Neutral | UBS AG | |
| 06.08.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.08.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 06.08.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 20.07.20 | Novo Nordisk Neutral | UBS AG | |
| 16.07.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.07.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 06.07.20 | A.P. Moeller - Maersk A-S (B) buy | Deutsche Bank AG | |
| 02.07.20 | A.P. Moeller - Maersk A-S (B) Underweight | Barclays Capital | |
| 22.06.20 | Novo Nordisk Neutral | Oddo BHF | |
| 19.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 19.06.20 | A.P. Moeller - Maersk A-S (B) neutral | Jefferies & Company Inc. | |
| 17.06.20 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 17.06.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 16.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 15.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 12.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 12.06.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.06.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. |